

09/462845
GC382 - PCT
PCUS 98/14647



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

17 SEP 1998

REC'D

Bescheinigung Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

97305232.7

PRIORITY DOCUMENT

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

M.B. RIJLING

DEN HAAG, DEN
THE HAGUE, 17/08/98
LA HAYE, LE

EP/US 98/14647
REC 31 AUG 1998



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

**Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**

Anmeldung Nr.:
Application no.: 97305232.7
Demande n°:

Anmeldetag:
Date of filing: 15/07/97
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
Genencor International B.V.
2600 AP Delft
NETHERLANDS

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Proteases from gram-positive organisms

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat State Pays Tag Date Date

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation
International Patent classification
Classification internationale des brevets

/

Am Anmeldetag benannte Vertragstaaten
Contracting states designated at date of filing AT/BE/CH/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt

Bemerkungen
Remarks
Remarques.

PATENT
Docket No. GC 382

PROTEASES FROM GRAM-POSITIVE ORGANISMS

FIELD OF THE INVENTION

The present invention relates to serine proteases derived from gram-positive microorganisms. The present invention provides nucleic acid and amino acid sequences of serine protease 1, 2, 3, 4 and 5 identified in *Bacillus*. The present invention also provides methods for the production of serine protease 1, 2, 3, 4 and 5 in host cells as well as the production of heterologous proteins in a host cell having a mutation or deletion of part or all of at least one of the serine proteases of the present invention.

BACKGROUND OF THE INVENTION

Gram-positive microorganisms, such as members of the group *Bacillus*, have been used for large-scale industrial fermentation due, in part, to their ability to secrete their fermentation products into the culture media. In gram-positive bacteria, secreted proteins are exported across a cell membrane and a cell wall, and then are subsequently released into the external media usually maintaining their native conformation.

Various gram-positive microorganisms are known to secrete extracellular and/or intracellular protease at some stage in their life cycles. Many proteases are produced in large quantities for industrial purposes. A negative aspect of the presence of proteases in gram-positive organisms is their contribution to the overall degradation of secreted heterologous or foreign proteins.

The classification of proteases found in microorganisms is based on their catalytic mechanism which results in four groups: the serine proteases; metalloproteases; cysteine proteases; and aspartic proteases. These categories can be distinguished by their sensitivity to various inhibitors. For example, the serine proteases are inhibited by phenylmethylsulfonylfluoride (PMSF) and diisopropylfluorophosphate (DIFP); the metalloproteases by chelating agents; the cysteine enzymes by iodoacetamide and heavy metals and the aspartic proteases by pepstatin. The serine proteases have alkaline pH optima, the metalloproteases are optimally active around neutrality, and the cysteine and aspartic enzymes have

acidic pH optima (Biotechnology Handbooks, Bacillus, vol. 2, edited by Harwood, 1989 Plenum Press, New York).

Proteolytic enzymes that are dependent upon a serine residue for catalytic activity are called serine proteases. As described in Methods in Enzymology, vol. 244, Academic Press, Inc. 1994, page 21, serine proteases of the family S9 have the catalytic residue triad "Ser-Asp-His with conservation of amino acids around them.

SUMMARY OF THE INVENTION

The present invention relates to the unexpected discovery of five heretofore unknown or unrecognized S9 type serine proteases found in uncharacterized translated genomic nucleic acid sequences of *Bacillus subtilis*, designated herein as SP1, SP2, SP3, SP4 and SP5 having the nucleic acid and amino acid as shown in the Figures. The present invention is based, in part, upon the presence the amino acid triad S-D-H in the five serine proteases, as well as amino acid conservation around the triad. The present invention is also based in part upon the heretofore uncharacterized or unrecognized overall amino acid relatedness that SP1, SP2, SP3, SP4 and SP5 have with the serine protease dipeptidyl-amino peptidase B from yeast (DAP) and with each other.

The present invention provides isolated polynucleotide and amino acid sequences for SP1, SP2, SP3, SP4 and SP5. Due to the degeneracy of the genetic code, the present invention encompasses any nucleic acid sequence that encodes the SP1, SP2, SP3, SP4 and SP5 deduced amino acid sequences shown in Figures 2A-2B-Figure 6, respectively.

The present invention encompasses amino acid variations of *B. subtilis* SP1, SP2, SP3, SP4 and SP5 amino acids disclosed herein that have proteolytic activity. *E. subtilis* SP1, SP2, SP3, SP4 and SP5 as well as proteolytically active amino acid variations, thereof have application in cleaning compositions. The present invention also encompasses amino acid variations or derivatives of SP1, SP2, SP3, SP4 and SP5 that do not have the characteristic proteolytic activity as long as the nucleic acid sequences encoding such variations or derivatives would have sufficient 5' and 3' coding regions to be capable of integration into a gram-positive organism genome. Such variants would have applications in gram-positive expression systems where it is desirable to delete, mutate, alter or otherwise incapacitate the naturally occurring serine protease in order to diminish or delete its proteolytic activity. Such an

expression system would have the advantage of allowing for greater yields of recombinant heterologous proteins or polypeptides.

The present invention provides methods for detecting gram positive microorganism homologs of *B. subtilis* SP1, SP2, SP3, SP4 and SP5 that comprises hybridizing part or all of the nucleic acid encoding *B. subtilis* SP1, SP2, SP3, SP4 or SP45 with nucleic acid derived from gram-positive organisms, either of genomic or cDNA origin. In one embodiment, the gram-positive microorganism is selected from the group consisting of *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. lautus* and *Bacillus thuringiensis*.

The production of desired heterologous proteins or polypeptides in gram-positive microorganisms may be hindered by the presence of one or more proteases which degrade the produced heterologous protein or polypeptide. One advantage of the present invention is that it provides methods and expression systems which can be used to prevent that degradation, thereby enhancing yields of the desired heterologous protein or polypeptide.

Thus, in another aspect, the present invention provides a gram-positive microorganism having a mutation or deletion of part or all of the gene encoding SP1 and/or SP2 and/or SP3 and/or SP4 and/or SP5 which results in inactivation of their proteolytic activity, either alone or in combination with mutations in other proteases, such as apr, npr, epr, mpr for example, or other proteases known to those of skill in the art. In one embodiment of the present invention, the gram-positive organism is a member of the genus *Bacillus*. In another embodiment, the *Bacillus* is *Bacillus subtilis*.

In yet another aspect, the gram-positive host is genetically engineered to produce a desired protein. In one embodiment of the present invention, the desired protein is heterologous to the gram-positive host cell. In another embodiment, the desired protein is homologous to the host cell. The present invention encompasses a gram-positive host cell having a deletion or interruption of the nucleic acid encoding the naturally occurring homologous protein, such as a protease, and having nucleic acid encoding the homologous protein re-introduced in a recombinant form. In another embodiment, the host cell produces the homologous protein. Accordingly, the present invention also provides methods and expression systems for reducing degradation of heterologous proteins produced in gram-positive microorganisms. The gram-positive microorganism may be normally sporulating or non-sporulating.

In a further aspect of the present invention, gram-positive SP1, SP2, SP3, SP4 or SP5 is produced on an industrial fermentation scale in a microbial host expression system. In another aspect, isolated and purified recombinant SP1, SP2, SP3, SP4 or SP5 is used in compositions of matter intended for cleaning purposes, such as detergents. Accordingly, the present invention provides a cleaning composition comprising one or more of a gram-positive serine protease selected from the group consisting of SP1, SP2, SP3, SP4 and SP45. The serine protease may be used alone or in combination with other enzymes and/or mediators or enhancers.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1C shows the DNA and deduced amino acid sequence for SP1 (YUXL).

Figure 2A-2B show an amino acid alignment between DAP (dap2_yeast) and SP1 (YUXL). For Figures 2A-2B, 3 and 4, the amino acid triad S-D-H is indicated.

15 Figure 3 shows an amino acid alignment between SP1 (YUXL) and SP2 (YTMA).

Figure 4 shows an amino acid alignment between SP1 (YUXL) and SP3 (YITV).

20 Figure 5 shows an amino acid alignment between SP1 (YUXL) and SP4 (YQKD).

Figure 6 shows an amino acid alignment between SP1 (YUXL) and SP5 (CAH).

25 Figures 7A-7B shows the DNA and deduced amino acid sequence for SP2 (YTMA).

Figures 8A-8B shows the DNA and deduced amino acid sequence for SP3 (YITV).

30 Figures 9A-9B shows the DNA and deduced amino acid sequence for SP4 (YQKD).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Definitions

As used herein, the genus *Bacillus* includes all members known to those of skill in the art, including but not limited to *B. subtilis*, *B. licheniformis*, *B. lentus*, *B.*

brevis, *B. stearothermophilus*, *B. alkalophilus*, *B. amylolyquefaciens*, *B. coagulans*, *B. ciculans*, *B. lautus* and *B. thuringiensis*.

The present invention encompasses novel SP1, SP2, SP3, SP4 and SP5 from gram positive organisms. In a preferred embodiment, the gram-positive organisms is a *Bacillus*. In another preferred embodiment, the gram-positive organism is *Bacillus subtilis*. As used herein, "*B. subtilis* SP1 (YuxL) refers to the DNA and deduced amino acid sequence shown in Figures 1A-1C and Figures 2A-2B; SP2 (YtmA) refers to the DNA and deduced amino acid sequence shown in Figures 7A-7B and Figure 3; SP3 (YitV) refers to the DNA and deduced amino acid sequence shown in Figures 8A-8B and Figure 4; SP4 (YqkD) refers to the DNA and deduced amino acid sequence shown in Figures 9A-9B and Figure 5; and SP5 (CAH) refers to the deduced amino acid sequence shown in Figure 6. The present invention encompasses amino acid variations of the *B. subtilis* amino acid sequences of SP1, SP2, SP3, SP4 and SP5 that have proteolytic activity. Such proteolytic amino acid variants can be used in cleaning compositions. The present invention also encompasses *B. subtilis* amino acid variations or derivatives that are not proteolytically active. DNA encoding such variants can be used in methods designed to delete or mutate the naturally occurring host cell SP1, SP2, SP3, SP4 and SP5.

As used herein, "nucleic acid" refers to a nucleotide or polynucleotide sequence, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be double-stranded or single-stranded, whether representing the sense or antisense strand. As used herein "amino acid" refers to peptide or protein sequences or portions thereof. A "polynucleotide homolog" as used herein refers to a novel gram-positive microorganism polynucleotide that has at least 80%, at least 90% and at least 95% identity to *B. subtilis* SP1, SP2, SP3, SP4 or SP5, or which is capable of hybridizing to *B. subtilis* SP1, SP2, SP3, SP4 or SP5 under conditions of high stringency and which encodes an amino acid sequence having serine protease activity.

The terms "isolated" or "purified" as used herein refer to a nucleic acid or amino acid that is removed from at least one component with which it is naturally associated.

As used herein, the term "heterologous protein" refers to a protein or polypeptide that does not naturally occur in a gram-positive host cell. Examples of heterologous proteins include enzymes such as hydrolases including proteases, cellulases, amylases, carbohydrases, and lipases; isomerases such as racemases,

epimerases, tautomerases, or mutases; transferases, kinases and phosphatases. The heterologous gene may encode therapeutically significant proteins or peptides, such as growth factors, cytokines, ligands, receptors and inhibitors, as well as vaccines and antibodies. The gene may encode commercially important industrial 5 proteins or peptides, such as proteases, carbohydrases such as amylases and glucoamylases, cellulases, oxidases and lipases. The gene of interest may be a naturally occurring gene, a mutated gene or a synthetic gene.

The term "homologous protein" refers to a protein or polypeptide native or naturally occurring in a gram-positive host cell. The invention includes host cells 10 producing the homologous protein via recombinant DNA technology. The present invention encompasses a gram-positive host cell having a deletion or interruption of the nucleic acid encoding the naturally occurring homologous protein, such as a protease, and having nucleic acid encoding the homologous protein re-introduced in a recombinant form. In another embodiment, the host cell produces the homologous 15 protein.

As used herein, the term "overexpressing" when referring to the production of a protein in a host cell means that the protein is produced in greater amounts than its production in its naturally occurring environment.

As used herein, the phrase "proteolytic activity" refers to a protein that is able 20 to hydrolyze a peptide bond. Enzymes having proteolytic activity are described in Enzyme Nomenclature. 1992, edited Webb Academic Press, Inc.

Detailed Description of the Preferred Embodiments

The unexpected discovery of the serine proteases SP1, SP2, SP3, SP4 and 25 SP5 in *B. subtilis* provides a basis for producing host cells, expression methods and systems which can be used to prevent the degradation of recombinantly produced heterologous proteins. In a preferred embodiment, the host cell is a gram-positive 30 host cell that has a reduction or mutation in the naturally occurring serine protease said mutation resulting in the complete deletion or inactivation of the production by the host cell of the proteolytic serine protease gene product. In another embodiment of the present invention, the host cell is additionally genetically engineered to produce a desired protein or polypeptide.

It may also be desired to genetically engineer host cells of any type to 35 produce a gram-positive serine protease SP1, SP2, SP3, SP4 or SP5. Such host

cells are used in large scale fermentation to produce large quantities of the serine protease which may be isolated or purified and used in cleaning products, such as detergents.

I. Serine protease Sequences

5 The SP1, SP2, SP3 and SP4 polynucleotides having the sequences as shown in the Figures encode the *Bacillus subtilis* serine SP1, SP2, SP3, and SP4. As will be understood by the skilled artisan, due to the degeneracy of the genetic code, a variety of polynucleotides can encode the *Bacillus* SP1, SP2, SP3, SP4 and SP5. The present invention encompasses all such polynucleotides.

10 The present invention encompasses novel SP1, SP2, SP3, SP4 and SP5 polynucleotide homologs encoding gram-positive microorganism serine proteases SP1, SP2, SP3, SP4 and SP5, respectively, which have at least 80%, or at least 90% or at least 95% identity to *B. subtilis* as long as the homolog encodes a protein that has proteolytic activity.

15 Gram-positive polynucleotide homologs of *B. subtilis* SP1, SP2, SP3, SP4 or SP5 may be obtained by standard procedures known in the art from, for example, cloned DNA (e.g., a DNA "library"), genomic DNA libraries, by chemical synthesis once identified, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from a desired cell. (See, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) A preferred source is from genomic DNA. Nucleic acid sequences derived from genomic DNA may contain regulatory regions in addition to coding regions. Whatever the source, the isolated serine protease gene should be molecularly cloned into a suitable vector for propagation of the gene.

20 In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

25 Once the DNA fragments are generated, identification of the specific DNA fragment containing the SP1, SP2, SP3, SP4 or SP5 may be accomplished in a number of ways. For example, a *B. subtilis* SP1, SP2, SP3, SP4 or SP5 gene of the

present invention or its specific RNA, or a fragment thereof, such as a probe or primer, may be isolated and labeled and then used in hybridization assays to detect a gram-positive SP1, SP2, SP3, SP4 or SP5 gene. (Benton, W. and Davis, R., 1977, Science 196:180; Grunstein, M. And Hogness, D., 1975, Proc. Natl. Acad. Sci. USA 72:3961). Those DNA fragments sharing substantial sequence similarity to the probe will hybridize under stringent conditions.

Accordingly, the present invention provides a method for the detection of gram-positive SP1, SP2, SP3, SP4 or SP5 polynucleotide homologs which comprises hybridizing part or all of a nucleic acid sequence of *B. subtilis* SP1, SP2, 10 SP3, SP4 or SP5 with gram-positive microorganism nucleic acid of either genomic or cDNA origin.

Also included within the scope of the present invention are gram-positive microorganism polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of *B. subtilis* SP1, SP2, SP3, SP4 or SP5 under conditions of 15 intermediate to maximal stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA) incorporated herein by reference, and confer a defined "stringency" as explained below.

"Maximum stringency" typically occurs at about T_m -5°C (5°C below the T_m of the probe); "high stringency" at about 5°C to 10°C below T_m ; "intermediate stringency" at about 10°C to 20°C below T_m ; and "low stringency" at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs.

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY).

30 The process of amplification as carried out in polymerase chain reaction (PCR) technologies is described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY). A nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides from *B. subtilis* SP1, SP2, SP3, SP4 or SP5 preferably about 12 to 30 nucleotides, and more preferably about 20-25 nucleotides can be used as a probe or PCR primer.

The *B. subtilis* amino acid sequences SP1, SP2, SP3, SP4 and SP5 (shown in Figures 2A-2B through Figure 6) were identified via a FASTA search of *Bacillus subtilis* genomic nucleic acid sequences. *B. subtilis* SP1 (YuxL) was identified by its structural homology to the serine protease DAP classified as an S9 type serine protease, designated in Figures 2A-2B as "dap2_yeast". As shown in Figures 2A-2B, SP1 has the amino acid dyad "S-D-H" indicated. Conservation of amino acids around each residue is noted in Figures 2A-2B through Figure 6. SP2 (YtmA); SP3 (YitV); SP4 (YqkD0 and SP5 (CAH) were identified upon by their structural and overall amino acid homology to SP1 (YuxL). SP1 and SP4 were described in Parsot and Kebayashi, respectively, but were not characterized as serine proteases or serine proteases of the S9 family.

II. Expression Systems

The present invention provides host cells, expression methods and systems for the enhanced production and secretion of desired heterologous or homologous proteins in gram-positive microorganisms. In one embodiment, a host cell is genetically engineered to have a deletion or mutation in the gene encoding a gram-positive SP1, SP2, SP3, SP4 or SP5 such that the respective activity is deleted. In an alternative embodiment of the present invention, a gram-positive microorganism is genetically engineered to produce a serine protease of the present invention.

Inactivation of a gram-positive serine protease in a host cell

Producing an expression host cell incapable of producing the naturally occurring serine protease necessitates the replacement and/or inactivation of the naturally occurring gene from the genome of the host cell. In a preferred embodiment, the mutation is a non-reverting mutation.

One method for mutating nucleic acid encoding a gram-positive serine protease is to clone the nucleic acid or part thereof, modify the nucleic acid by site directed mutagenesis and reintroduce the mutated nucleic acid into the cell on a plasmid. By homologous recombination, the mutated gene may be introduced into the chromosome. In the parent host cell, the result is that the naturally occurring nucleic acid and the mutated nucleic acid are located in tandem on the chromosome. After a second recombination, the modified sequence is left in the chromosome having thereby effectively introduced the mutation into the chromosomal gene for progeny of the parent host cell.

Another method for inactivating the serine protease proteolytic activity is through deleting the chromosomal gene copy. In a preferred embodiment, the entire gene is deleted, the deletion occurring in such a way as to make reversion impossible. In another preferred embodiment, a partial deletion is produced, provided that the nucleic acid sequence left in the chromosome is too short for homologous recombination with a plasmid encoded serine protease gene. In another preferred embodiment, nucleic acid encoding the catalytic amino acid residues are deleted.

Deletion of the naturally occurring gram-positive microorganism serine protease can be carried out as follows. A serine protease gene including its 5' and 3' regions is isolated and inserted into a cloning vector. The coding region of the serine protease gene is deleted from the vector *in vitro*, leaving behind a sufficient amount of the 5' and 3' flanking sequences to provide for homologous recombination with the naturally occurring gene in the parent host cell. The vector is then transformed into the gram-positive host cell. The vector integrates into the chromosome via homologous recombination in the flanking regions. This method leads to a gram-positive strain in which the protease gene has been deleted.

The vector used in an integration method is preferably a plasmid. A selectable marker may be included to allow for ease of identification of desired recombinant microorganisms. Additionally, as will be appreciated by one of skill in the art, the vector is preferably one which can be selectively integrated into the chromosome. This can be achieved by introducing an inducible origin of replication, for example, a temperature sensitive origin into the plasmid. By growing the transformants at a temperature to which the origin of replication is sensitive, the replication function of the plasmid is inactivated, thereby providing a means for selection of chromosomal integrants. Integrants may be selected for growth at high temperatures in the presence of the selectable marker, such as an antibiotic. Integration mechanisms are described in WO 88/06623.

Integration by the Campbell-type mechanism can take place in the 5' flanking region of the protease gene, resulting in a protease positive strain carrying the entire plasmid vector in the chromosome in the serine protease locus. Since illegitimate recombination will give different results it will be necessary to determine whether the complete gene has been deleted, such as through nucleic acid sequencing or restriction maps.

Another method of inactivating the naturally occurring serine protease gene is to mutagenize the chromosomal gene copy by transforming a gram-positive microorganism with oligonucleotides which are mutagenic. Alternatively, the chromosomal serine protease gene can be replaced with a mutant gene by homologous recombination.

The present invention encompasses host cells having additional protease deletions or mutations, such as deletions or mutations in apr, npr, epr, mpr and others known to those of skill in the art.

10 III. Production of Serine protease

For production of serine protease in a host cell, an expression vector comprising at least one copy of nucleic acid encoding a gram-positive microorganism SP1, SP2, SP3, SP4 or SP5, and preferably comprising multiple copies, is transformed into the host cell under conditions suitable for expression of the serine protease. In accordance with the present invention, polynucleotides which encode a gram-positive microorganism SP1, SP2, SP3, SP4 or SP5, or fragments thereof, or fusion proteins or polynucleotide homolog sequences that encode amino acid variants of B. SP1, SP2, SP3, SP4 or SP5, may be used to generate recombinant DNA molecules that direct their expression in host cells. In a preferred embodiment, the gram-positive host cell belongs to the genus *Bacillus*. In another preferred embodiment, the gram positive host cell is *B. subtilis*.

As will be understood by those of skill in the art, it may be advantageous to produce polynucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular gram-positive host cell (Murray E et al (1989) Nuc Acids Res 17:477-508) can be selected, for example, to increase the rate of expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

Altered SP1, SP2, SP3, SP4 or SP5 polynucleotide sequences which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotide residues resulting in a polynucleotide that encodes the same or a functionally equivalent SP1, SP2, SP3, SP4 or SP5 homolog, respectively. As used herein a "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

As used herein an "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring SP1, SP2, SP3, SP4 or SP5.

5 As used herein "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

The encoded protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally SP1, SP2, SP3, SP4 or SP5 variant. Deliberate amino acid substitutions may be made 10 on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the variant retains the ability to modulate secretion. For example, negatively charged amino acids include 15 aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine, phenylalanine, and tyrosine.

The SP1, SP2, SP3, SP4 or SP5 polynucleotides of the present invention may be engineered in order to modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques 20 which are well known in the art, e.g., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns or to change codon preference, for example.

In one embodiment of the present invention, a gram-positive microorganism 25 SP1, SP2, SP3, SP4 or SP5 polynucleotide may be ligated to a heterologous sequence to encode a fusion protein. A fusion protein may also be engineered to contain a cleavage site located between the serine protease nucleotide sequence and the heterologous protein sequence, so that the serine protease may be cleaved and purified away from the heterologous moiety.

30 IV. Vector Sequences

Expression vectors used in expressing the serine proteases of the present invention in gram-positive microorganisms comprise at least one promoter associated with a serine protease selected from the group consisting of SP1, SP2, SP3, SP4 and SP5, which promoter is functional in the host cell. In one embodiment 35 of the present invention, the promoter is the wild-type promoter for the selected

serine protease and in another embodiment of the present invention, the promoter is heterologous to the serine protease, but still functional in the host cell. In one preferred embodiment of the present invention, nucleic acid encoding the serine protease is stably integrated into the microorganism genome.

5 In a preferred embodiment, the expression vector contains a multiple cloning site cassette which preferably comprises at least one restriction endonuclease site unique to the vector, to facilitate ease of nucleic acid manipulation. In a preferred embodiment, the vector also comprises one or more selectable markers. As used herein, the term selectable marker refers to a gene capable of expression in the
10 gram-positive host which allows for ease of selection of those hosts containing the vector. Examples of such selectable markers include but are not limited to antibiotics, such as, erythromycin, actinomycin, chloramphenicol and tetracycline.

V. Transformation

15 A variety of host cells can be used for the production of SP1, SP2, SP3, SP4 or SP5 including bacterial, fungal, mammalian and insects cells. General transformation procedures are taught in Current Protocols In Molecular Biology (vol. 1, edited by Ausubel et al., John Wiley & Sons, Inc. 1987, Chapter 9) and include calcium phosphate methods, transformation using DEAE-Dextran and
20 electroporation. Plant transformation methods are taught in Rodriguez (WO 95/14099, published 26 May 1995).

25 In a preferred embodiment, the host cell is a gram-positive microorganism and in another preferred embodiment, the host cell is *Bacillus*. In one embodiment of the present invention, nucleic acid encoding one or more serine protease(s) of the present invention is introduced into a host cell via an expression vector capable of replicating within the host cell. Suitable replicating plasmids for *Bacillus* are described in Molecular Biological Methods for *Bacillus*, Ed. Harwood and Cutting, John Wiley & Sons, 1990, hereby expressly incorporated by reference; see chapter 3 on plasmids. Suitable replicating plasmids for *B. subtilis* are listed on page 92.

30 In another embodiment, nucleic acid encoding a serine protease(s) of the present invention is stably integrated into the microorganism genome. Preferred host cells are gram-positive host cells. Another preferred host is *Bacillus*. Another preferred host is *Bacillus subtilis*. Several strategies have been described in the literature for the direct cloning of DNA in *Bacillus*. Plasmid marker rescue transformation involves the uptake of a donor plasmid by competent cells carrying a

partially homologous resident plasmid (Contente et al., *Plasmid* 2:555-571 (1979); Haima et al., *Mol. Gen. Genet.* 223:185-191 (1990); Weinrauch et al., *J. Bacteriol.* 154(3):1077-1087 (1983); and Weinrauch et al., *J. Bacteriol.* 169(3):1205-1211 (1987)). The incoming donor plasmid recombines with the homologous region of the resident "helper" plasmid in a process that mimics chromosomal transformation.

Transformation by protoplast transformation is described for *B. subtilis* in Chang and Cohen, (1979) *Mol. Gen. Genet.* 168:111-115; for *B. megaterium* in Vorobjeva et al., (1980) *FEMS Microbiol. Letters* 7:261-263; for *B. amyloliquefaciens* in Smith et al., (1986) *Appl. and Env. Microbiol.* 51:634; for *B. thuringiensis* in Fisher et al., (1981) *Arch. Microbiol.* 139:213-217; for *B. sphaericus* in McDonald (1984) *J. Gen. Microbiol.* 130:203; and *B. larvae* in Bakhiet et al., (1985) 49:577. Mann et al., (1986, *Current Microbiol.* 13:131-135) report on transformation of *Bacillus* protoplasts and Holubova, (1985) *Folia Microbiol.* 30:97) disclose methods for introducing DNA into protoplasts using DNA containing liposomes.

15

VI. Identification of Transformants

Whether a host cell has been transformed with a mutated or a naturally occurring gene encoding a gram-positive SP1, SP2, SP3, SP4 or SP5, detection of the presence/absence of marker gene expression can suggest whether the gene of interest is present. However, its expression should be confirmed. For example, if the nucleic acid encoding a serine protease is inserted within a marker gene sequence, recombinant cells containing the insert can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with nucleic acid encoding the serine protease under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the serine protease as well.

Alternatively, host cells which contain the coding sequence for a serine protease and express the protein may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane-based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the cysteine polynucleotide sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of *B. subtilis* SP1, SP2, SP3, SP4 or SP5.

VII Assay of Protease Activity

There are various assays known to those of skill in the art for detecting and measuring protease activity. There are assays based upon the release of acid-soluble peptides from casein or hemoglobin measured as absorbance at 280 nm or colorimetrically using the Folin method (Bergmeyer, et al., 1984, Methods of Enzymatic Analysis vol. 5, Peptidases, Proteinases and their Inhibitors, Verlag Chemie, Weinheim). Other assays involve the solubilization of chromogenic substrates (Ward, 1983, Proteinases, in Microbial Enzymes and Biotechnology (W.M. Fogarty, ed.), Applied Science, London, pp. 251-317).

VIII. Secretion of Recombinant Proteins

Means for determining the levels of secretion of a heterologous or homologous protein in a gram-positive host cell and detecting secreted proteins include, using either polyclonal or monoclonal antibodies specific for the protein. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, a Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 158:1211).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting specific polynucleotide sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the nucleotide sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567 and incorporated herein by reference.

IX Purification of Proteins

Gram positive host cells transformed with polynucleotide sequences encoding heterologous or homologous protein may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant gram-positive host cell comprising a serine protease of the present invention will be secreted into the culture media. Other recombinant constructions may join the heterologous or homologous polynucleotide sequences to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12:441-53).

Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath J (1992) Protein Expr Purif 3:263-281), protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and the heterologous protein can be used to facilitate purification.

20

X. Uses of The Present Invention

Genetically Engineered Host Cells

The present invention provides genetically engineered host cells comprising preferably non-revertable mutations or deletions in the naturally occurring gene encoding one or more of SP1, SP2, SP3, SP4 or SP5 such that the proteolytic activity is diminished or deleted altogether. The host cell may contain additional protease deletions, such as deletions of the mature *subtilisin* protease and/or mature neutral protease disclosed in United States Patent No. 5,264,366.

In a preferred embodiment, the host cell is genetically engineered to produce a desired protein or polypeptide. In a preferred embodiment the host cell is a *Bacillus*. In another preferred embodiment, the host cell is a *Bacillus subtilis*.

In an alternative embodiment, a host cell is genetically engineered to produce a gram-positive SP1, SP2, SP3, SP4 or SP5. In a preferred embodiment, the host cell is grown under large scale fermentation conditions, the SP1, SP2, SP3, SP4 or

SP5 is isolated and/or purified and used in cleaning compositions such as detergents. WO 95/10615 discloses detergent formulation.

Polynucleotides

5 A *B.subtilis* SP1, SP2, SP3, SP4 or SP5 polynucleotide, or any part thereof, provides the basis for detecting the presence of gram-positive microorganism polynucleotide homologs through hybridization techniques and PCR technology.

Accordingly, one aspect of the present invention is to provide for nucleic acid hybridization and PCR probes which can be used to detect polynucleotide sequences, including genomic and cDNA sequences, encoding gram-positive SP1, 10 SP2, SP3, SP4 or SP5 or portions thereof.

The manner and method of carrying out the present invention may be more fully understood by those of skill in the art by reference to the following examples, 15 which examples are not intended in any manner to limit the scope of the present invention or of the claims directed thereto

Example I
Preparation of a Genomic library

20 The following example illustrates the preparation of a *Bacillus* genomic library.

Genomic DNA from *Bacillus* cells is prepared as taught in Current Protocols In Molecular Biology vol. 1, edited by Ausubel et al., John Wiley & Sons, Inc. 1987, chapter 2. 4.1. Generally, *Bacillus* cells from a saturated liquid culture are lysed and 25 the proteins removed by digestion with proteinase K. Cell wall debris, polysaccharides, and remaining proteins are removed by selective precipitation with CTAB, and high molecular weight genomic DNA is recovered from the resulting supernatant by isopropanol precipitation. If exceptionally clean genomic DNA is desired, an additional step of purifying the *Bacillus* genomic DNA on a cesium chloride gradient is added.

30 After obtaining purified genomic DNA, the DNA is subjected to Sau3A digestion. Sau3A recognizes the 4 base pair site GATC and generates fragments compatible with several convenient phage lambda and cosmid vectors. The DNA is subjected to partial digestion to increase the chance of obtaining random fragments.

35 The partially digested *Bacillus* genomic DNA is subjected to size fractionation on a 1% agarose gel prior to cloning into a vector. Alternatively, size fractionation on a sucrose gradient can be used. The genomic DNA obtained from the size

fractionation step is purified away from the agarose and ligated into a cloning vector appropriate for use in a host cell and transformed into the host cell.

Example II

5 The following example describes the detection of gram-positive microorganism SP1. The same procedures can be used to detect SP2, SP3, SP4 or SP5.

10 DNA derived from a gram-positive microorganism is prepared according to the methods disclosed in Current Protocols in Molecular Biology, Chap. 2 or 3. The nucleic acid is subjected to hybridization and/or PCR amplification with a probe or primer derived from SP1. A preferred probe comprises the nucleic acid section encoding conserved amino acid residues.

15 The nucleic acid probe is labeled by combining 50 pmol of the nucleic acid and 250 mCi of [gamma ³²P] adenosine triphosphate (Amersham, Chicago IL) and T4 polynucleotide kinase (DuPont NEN®, Boston MA). The labeled probe is purified with Sephadex G-25 super fine resin column (Pharmacia). A portion containing 10⁷ counts per minute of each is used in a typical membrane based hybridization analysis of nucleic acid sample of either genomic or cDNA origin.

20 The DNA sample which has been subjected to restriction endonuclease digestion is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40 degrees C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. The blots are exposed to film for several hours, the film developed and hybridization patterns are compared visually to detect polynucleotide homologs of *B. subtilis* SP1. The homologs are subjected to confirmatory nucleic acid sequencing. Methods for nucleic acid sequencing are well known in the art. Conventional enzymatic methods employ DNA polymerase Klenow fragment, SEQUENASe® (US Biochemical Corp, Cleveland, OH) or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest.

25 Various other examples and modifications of the foregoing description and examples will be apparent to a person skilled in the art after reading the disclosure without departing from the spirit and scope of the invention, and it is intended that all such examples or modifications be included within the scope of the appended claims. All publications and patents referenced herein are hereby incorporated in their entirety.

CLAIM

We claim:

- 5 1. An isolated polynucleotide encoding SP2 from a gram positive microorganism.
2. The polynucleotide of Claim 1 wherein SP2 has the amino acid sequence shown in Figures 7A-7B.
- 10 3. An isolated SP2 encoding nucleic acid having the nucleic acid sequence as shown in Figures 7A-7B.
4. An isolated SP2 from a gram-positive microorganism.
- 15 5. The isolated SP2 of Claim 4 having the amino acid sequence as shown in Figure 7A-7B.
6. An isolated polynucleotide encoding SP3 from a gram positive microorganism.
- 20 7. The polynucleotide of Claim 6 wherein SP3 has the amino acid sequence shown in Figures 8A-8B.
8. The isolated SP3 encoding nucleic acid having the sequence as shown in Figure 8A-8B.
- 25 9. An isolated SP3 from a gram-positive microorganism.
10. The isolated SP3 of Claim 9 having the amino acid sequence as shown in Figures 8A-8B.
- 30 11. A gram-positive microorganism having a mutation or deletion of part or all of one or more of the genes encoding serine proteases selected from the group consisting of SP1, SP2, SP3, SP4 and SP5 said mutation or deletion resulting in the inactivation of the CP1 proteolytic activity.
- 35 12. The gram-positive microorganism according to Claims 11 that is a member of the family *Bacillus*.

13. The microorganism according to Claim 12 wherein the member is selected from the group consisting of *B. licheniformis*, *B. lentinus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. laetus* and
5 *Bacillus thuringiensis*.
14. The microorganism of Claim 11 wherein said microorganism is capable of
expressing a heterologous protein.
- 10 15. The microorganism of Claim 14 wherein said heterologous protein is selected from the group consisting of hormone, enzyme, growth factor and cytokine.
16. The host cell of Claim 15 wherein said heterologous protein is an enzyme.
- 15 17. The host cell of Claim 16 wherein said enzyme is selected from the group consisting of a proteases, carbohydrases, and lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases and phosphatases.
- 20 18. A cleaning composition comprising a serine protease selected from the group consisting of SP1, SP2, SP3, SP4 and SP5.
19. An expression vector comprising nucleic acid encoding a serine protease selected from the group consisting of SP1, SP2, SP3, SP5 or SPS.
- 25 22. A host cell comprising an expression vector according to Claim 21.

ABSTRACT

The present invention relates to the identification of novel serine proteases in Gram-positive microorganisms. The present invention provides the nucleic acid and amino acid sequences for the *Bacillus subtilis* serine proteases SP1, SP2, SP3, SP4 and SP5. The present invention also provides host cells having a mutation or deletion of part or all of the gene encoding SP1, SP2, SP3, SP4 and SP5. The present invention also provides host cells further comprising nucleic acid encoding desired heterologous proteins such as enzymes. The present invention also provides a cleaning composition comprising a serine protease of the present invention.

6

10	30	
atgaaaaagctgataaccgcagacgacatcacagcgattgtctctgtg		
M K K L I T A D D I T A I V S V		
50	70	90
accgatcctcaatacgcggcagacggtagccgtgccgcataatgtaaaa		
T D P Q Y A P D G T R A A Y V K		
110	130	
tcacaagtaaatcaagagaaaagattcgtatacatcaaatatatggatc		
S Q V N Q E K D S Y T S N I W I		
150	170	190
tatgaaacgaaaacgggaggatctgttccctggacacatggagaaaag		
Y E T K T G G S V P W T H G E K		
210	230	
cgaaggcaccgacccaagatggtctccggacggcgacgcttgccctt		
R S T D P R W S P D G R T L A F		
250	270	2
atttctgatcgagaaggcgatcgccacagctttatcatgagcact		
I S D R E G D A A Q L Y I M S T		
90	310	330
gaaggcggagaagcaagaaaactgactgatcatccatatggcgtgtca		
E G G E A R K L T D I P Y G V S		
350	370	
aagccgctatggtccccggacggtaatcgattctggtcactatcagt		
K P L W S P D G E S I L V T I S		
390	410	430
ttgggagagggggaaagcattgatgaccgagaaaaaacagagcaggac		
L G E G E S I D D R E K T E Q D		
450	470	
agctatgaacctgttgaagtgcacggctctccataaaacgggacggc		
S Y E P V E V Q G L S Y K R D G		
490	510	5
aaaggcgtacgagagggtgcgtatgcccagcttgcgttcagcgta		
K G L T R G A Y A Q L V L V S V		
30	550	570
aagtccgggtgagatgaaagagactgacaaggcacaaagctgatcatggt		
K S G E M K E L T S H K A D H G		
590	610	
gatccctgcctttctcgtacggcaaattggcttgcgttcagctaatt		
D P A F S P D G K W L V F S A N		
630	650	670
ttaactgaaacagatgatgccagcaagccgatgatgtttacataatg		
L T E T D D A S K P H D V Y I M		
690	710	

GC 382

Figure 1A

2/15

tcactggagtcggagatcttaagcaggtaacacccatcgccgctca
 S L E S G D L K Q V T P H R G S
 730 750 7
 ttccggatcaagctcatttcaccagacgaaaggatcttgctttgctt
 F G S S S F S P D G R Y L A L L
 790 810
 ggaatgaaaaggaatataagaatgtcacgcctcaaaggcgtggctc
 G N E K E Y K N A T L S K A W L
 830 850
 tatgatatcgaacaaggccgcctcacatgtttactgagatgctggac
 Y D I E Q G R L T C L T E M L D
 870 890 910
 gttcatttagcgatgcgctgattggagattcattgatcggtggct
 V H L A D A L I G D S L I G G A
 930 950
 gaacagcgcccgatttggacaaaggacagccaagggtttatgtcatc
 E Q R P I W T K D S Q G F Y V I
 970 990 10
 ggcacagatcaaggcagtacggcatctattatattcgattgaaggc
 G T D Q G S T G I Y Y I S I E G
 10 1030 1050
 cttgttatccgattcgtctggaaaaagagtacatcaatagctttct
 L V Y P I R L E K E Y I N S F S
 1070 1090
 cttdcacctgatgaacacgactttattgcgcgtgtgacaaagccggac
 L S P D E Q H F I A S V T K P D
 1110 1130 1150
 agaccgagttagttacagtatccgctggacaggaagagaaacag
 R P S E L Y S I P L G Q E E K Q
 1170 1190
 ctgactggcgcaatgacaagttgtcagggagcatacgatata
 L T G A N D K F V R E H T I S I
 1210 1230 12
 cctgaagagattcaatatgtacagaagacggcgtgatggtaacggc
 P E E I Q Y A T E D G V M V N G
 50 1270 1290
 tggctgatgaggcctgcacaaatgaaaggtagacacaatccactt
 W L M R P A Q M E G E T T Y P L
 1310 1330
 attcttaacatacagggcggtccgcatatgtatgtacggacatacatat
 I L N I H G G P H M M Y G H T Y
 1350 1370 1390
 tttcatgagttcaggtgctggccggcgaaggatacgcgtcgat
 F H E F Q V L A A K G Y A V V Y
 1410 1430

6C382

Figure 1B

319

atcaatccgagaggaaggccacggctacggcaggaatttgtaatgcg
 I N P R G S H G Y G Q E F V N A

1450	1470	14
gtcagaggagattatggggaaaggattatgacgatgtatgcaggct		
V R G D Y G G K D Y D D V M Q A		

90	1510	1530
gtggatgaggctatcaaacgagatccgcatattgatctaagcggctc		
V D E A I K R D P H I D P K R L		

1550	1570	
ggtgtcacggcggaagctacggaggtttatgaccaactggatcgtc		
G V T G G S Y G G F M T N W I V		

1590	1610	1630
gggcagacgaaccgctttaaagctgccgttacccagcgctcgatata		
G Q T N R F K A A V T Q R S I S		

1650	1670	
aattggatcagttcacggcgtcagtgatatacggttattttaca		
N W I S F H G V S D I G Y F F T		

1690	1710	17
gactggcagcttgagcatgacatgtttgaggacacagaaaagctctgg		
D W Q L E H D M F E D T E K L W		

30	1750	1770
gaccggctccctttaaaatacgcagcaaacgtggagacaccgctttg		
D R S P L K Y A A N V E T P L L		

1790	1810	
atactgcattggcgagcgggatgaccgatgcccgtatcgagcaggcggag		
I L H G E R D D R C P I E Q A E		

1830	1850	1870
cagctgtttatcgctctgaaaaaaaaatggcaaggaaaccaagcttgtc		
Q L F I A L K K M G K E T K L V		

1890	1910	
cgtttccgaatgcattgcacaaatttatcacgcacccgacacccaaga		
R F P N A S H N L S R T G H P R		

1930	1950	19
cagcggatcaagcgctgaatttatcagctcatggttgatcaacat		
Q R I K R L N Y I S S W F D Q H		

70
ctc
L

GC 382 Figure 1C

4/15

SCORES Initl: 58 Initn: 165 Opt: 204 z-score: 227.4 E(): 3e-0
 7
 Smith-Waterman score: 235; 20.3% identity in 646 aa overlap

	170	180	190	200	210	220
dap2_yeast	WRHSTFGSYFVYDKSSSFEEIGNEVALAIWSPNSNDIAYVQDN-NIYIYSAISKKTIRA					
YUXL	MKKLITADDITAIVSVTDPQYAPDGTRAAYVKSQVNQEKSYSNTSNIWIYE					
	10	20	30	40	50	
	230	240	250	260	270	280
dap2_yeast	VTNDGSSFLFNGKPDWVYEEEVFEDDKAAWWSPGTDYLAFLKIDESEVGEFIIPYYVQDE					
YUXL	TKTGGSV-----P-WTHGEKRSTDPR--WSPDGRTLAFISDREGDAQL---YIMSTE					
	60	70	80	90		
	290	300	310	320	330	
dap2_yeast	KDIYPPEMRSIKYPKSG---TPNPHAELWVYSMKDGTSHPRISGNKKDG--SLLITEVTW					
YUXL	GGEARKLTDIPYGVSPLWSPDGESILVTISLGEGESIDR-EKTEQDSYEPVEVQGLSY					
	100	110	120	130	140	150
	340	350	360	370	380	390
dap2_yeast	VGNGNVLVTTDRSSDILTIVFLIDTIAKTSNVVRNE---SSNGGWWEITHNTLFIPANE					
YUXL	KRDGKGLTRGAYAQLVLVSVKSGEMKELTSHKADHGDPAFSPDGKWLVFSAN---LTETD					
	160	170	180	190	200	210
	400	410	420	430	440	
dap2_yeast	TFDRPHNGYVDILPIGGYN---HLAYFENSNSS---HYKTLTEGKWEVVNGPLA---F					
YUXL	DASKPHDVYIMSLESGDLKQVTPHRGSFGSSFSPDGRLALLGNEKEYKNATLSKAWLY					
	220	230	240	250	260	270
	450	460	470	480	490	499
dap2_yeast	DSMENRLYFISTRKSSTERHVYYID-LRSPNEIIIEVTDTSEDGVYDVSFSSGRRFGL--L					
YUXL	DIEQGRLTCLTEMVDVHLADALIGDSLIGGAEQRPIWTKDSQGFYVIGTDQGST-GIYYI					
	280	290	300	310	320	330
	500	510	520	530	540	550
dap2_yeast	TYKGPKVVPYQKIVDFHSRKAEKCDKGNGVLGKSLYHLEKNEVLTKELEDYAVPR-KSFREL					
YUXL	SIEGLVYPIRLEKEYINSFSLSPDEQHFIASVTKPDRPSEL-----YSIPLGQEEKQL					
	340	350	360	370	380	
	560		570	580	590	600
dap2_yeast	NLGKDEFGKD-----ILVNSYEILPNDFDETLDHYPVFFFAYGGPNSQ					
YUXL	TGANDKFVREHTISIPEEIQYATEDGVMVNGWLMRPAQMEGETT--YPLILNIHGGPH-M					
	390	400	410	420	430	440

66382

Figure 2A

5 | 13

dap2_yeast	610	620	630	640	650	660
	QVVKTFSVGNEVVVASQLNAIVVVVVDGRGTGFKQDFRSVLVRDRLGDYEARDQISAAS-L					
YUXL	: : : : : : : : : : : : : : : : : :					
	MYGHTYFHEF-QVLAAKGYA-VVYINPRGSHGYGQEfvNAVRGDYGGKDYDDVMQAVDEA					
	450	460	470	480	490	500
	<i>↓ Serine</i>					
dap2_yeast	670	680	690	700	710	720
	YGSLTFVDPQKISLFGWSYGGYLTLKTLEKDGGRHFKYGMSVAPVTDWRFYDSVYTERYM					
YUXL	: : :: : : : : : : : : : : : : :					
	IKRDPHIDPKRLGVGGSYGGFMTNWIVGQTN--RFKAATQRSISNWISFHGVSDIGYF					
	510	520	530	540	550	
	<i>↓ Asp</i>					
dap2_yeast	730	740	750	760	770	
	HTP-QENFDGYVES-SVHNVTALAQNRR---FLLMHGTGDDNVHFQNSLKFLDDLNG					
YUXL	: : : : : : : : : : : : : : : :					
	FTDWQLEHDMFEDTEKLWDRSPLKYAANVETPLLILHGERDDRCPIEQAEQLFIALKKMG					
	560	570	580	590	600	610
	<i>↓ His</i>					
dap2_yeast	780	790	800	810		
	VENYDVHVFPDSDHISRYHNANVIVFDKLLDWAKRAFDGQFVK					
YUXL	: : : : :					
	KETKLVR-FPNASHNLSRTGHPRQRRIKRLNYISSWFDQHL					
	620	630	640	650		

GC382

Figure 2B

6 | 15

GC 382

Figure 3

+115

SCORES Initl: 58 Initn: 84 Opt: 153 z-score: 171.4 E(): 0.000
38
Smith-Waterman score: 153; 23.9% identity in 243 aa overlap

yuxl.bsupep	410 PEEIQYATEDGVMVNGWLMRPAQMEGETTYPLILNIHGGPHMMYGHTYFHEFQVLAAKGY
	:: : : : :
YITV	MIQIENQTVSGIPFLHIVKEENRHRAVPLVIFIHGFTSAKE-HN-LHIAYLLAEKG 10 20 30 40 50

yux1.bsupep	470	480	490	500		510
	AVVYINPRGSHGYGQE	FVN	AVRGDYGKDYDDVMQAVDEA	-----	IKRDPHIDPKRLGV	
	:	:	: ::	: :	: :	: ::
YITV	R	AVL	--PEALH-HGERGEEMAVEELAGHFWDIVLN	EIEIGVLKNHFEKEGLIDGGRIGL		
	60	70	80	90	100	110

yuxl.bsupep	520	530	540	550	560	570
	TGGSYGGFMTNWIYGQTNRFKAAVTQRSISNWISFHGVSDIGYFTDWQLEHDMFED-TE					
	: : : : : : : : : :: : :: :: : : : : ::					
YITV						
	AGTSMGGITTLGALTAYDWIKAGVSLMGS PNYVELFQ-QQIDHI-QSOGIEIDVPEEKVQ					
	↑ 120	130	140	150	160	170

yuxl.bsupep	580	590	600	610	620	
	KLWDRSPLKYAANV-----ETPLLILHGERDDRCPIEQAEQLFIALKKMGKET----KLV					
YITV	: : : : : : :: : : :					
	QLMKRLELRDLSLQPEKLOQRPLLFWHGAKDKVVVPYAPTRKFYDTIKSHYSEQPERLQFI					
	180	190	200	210	220	230
	↑ Asp					

	630	-	640	650
yuxl.bsupep	RFPNASHNLSRTGHPRQRKRLNYISSWFQHL			
	: ::	:	:	: :
YITV	GDENADHKV-----PRAAV--LKTIE-WFETYL			
	↑ HIS 240		250	

Figure 4

GC 382

8/15

SCORES Init1: 67 Initn: 67 Opt: 117 z-score: 131.5 E(): 0.06
 5
 Smith-Waterman score: 117; 21.6% identity in 232 aa overlap

yux1.bsupep	390	400	410	420	430	440
	TGANDKFVREHTISIPEEIQYATEDGVMVNGWLMRPAQMEEGETTYPLILNIHGGP-HMMY					
YQKD	: :: :: : : :::					
	40	50	60	70	80	90
yux1.bsupep	450	460	470	480	490	500
	GHTYFHEFQVLAAKGYAVVYINPRGSHGYGQEfvNAVRGDYGGKDYDDVMQAVDEAIKRD					
YQKD	: : : : : :: : : : :: : :: :					
	100	110	120	130	140	
yux1.bsupep	510	520	530	540	550	559
	PHIDPKRLGVTGGSYGGFMNTNWIVGQ----TNRFKAATQRSISNWISFHGVSDIGYFF					
YQKD	: : : : : :: : : :: : :: : : :					
	150	160	170	180	190	200
yux1.bsupep	560	570	580	590	600	610
	TDWQLEH--DMFEDTE---KLWDRSPLKYAANVETPLLILHGERDDRCPIEQAEQLFIAL					
YQKD	: : : : : : : : : : : :					
	210	220	230	240	250	260
yux1.bsupep	620	630	640	650		
	KKMGKETKLVRFPNASHNLSRTGHPRQRICKRLNYISSWFDQHL					
YQKD	:: : : :					
	270	280	290	300		

GC 382

Figure 5

9/15

SCORES Init1: 66 Initn: 90 Opt: 114 z-score: 128.0 E(): 0.

Smith-Waterman score: 152; 25.1% identity in 303 aa overlap

yux1.bsu pep 330 340 350 360 370 379
GTDQGSTGIYYISIEGLVYPIRLEKEYINSFSLSPDE-QHFIASVTKPDRPSELYSIPLG
CAH |:| |:| | : || ||:|:|
MQLFDLPLDQLQTYKPEKTAPKDFSEFWKLSLE
 10 20 30

yux1.bsu pep 380 390 400 410 420 430
QEEKQLTGANDKFVREHTISIP-EEIQYATEDGVMVNGWLMRPAQMEGETTYPLILNIHG
CAH :| :| :| :| :| :|
ELAKVQAEPDLQPVVDYPADGVKVYRLTYKSFGNARITGKYAVPDK-EGP--HPAIVKYHG
 40 50 60 70 80 90

yux1.bsu pep 440 450 460 470 480
GPHMMYGHFYHEFQVLAAGYAV-----VYINPRGSHGYGQEfvNAVRGD-
CAH :|: :||: | :||: :|:||:| | :|
YNASYDGE--IHEMVNWLHGYATFGMLVRGQQSSEDTSISPHG-HALGWMTKGILDKD
 100 110 120 130 140

yux1.bsu pep 490 500 510 520 530 540
--YGGKDYDDVMQAVDEAIKRDPHIDPKRLGVTGGSYGGFMTNWIVGQTNRFKAAVTQRS
CAH || ||:|:| ::| |:||||| || :| ::| |||:
YYYRGV-YLDAVRAL-EVISSFDEVDETRIGVTGGSQGGGLTIAAAALSDIPKAADVADYP
 150 160 170 180 ↑SER 190 200

yux1.bsu pep 550 560 570 580 590
-ISNWISFHGV-----DIGYFFT DWQLEHDMFEDTEKLWDRSPLKYAANVETPLLILH
CAH :||: -|: :|: || : :| :| :| :|:
YLSNFERAIDVALEQPYLEINSFRRNGSPETEVQAMKTLSYFDIMNLADRVKVPVLMSI
 210 220 230 240 250 260

yux1.bsu pep 600 610 620 630 640 650
GERDDRCPIEQAEQLFIALKKM--GKETKLVRFPNASHNLSRTGHPRQRKRLNYISSWF
CAH || | :| | ::| || |:
GLIDKVTP---PSTVFAAYNHLETKELKVYRYFGHEYIPAFQTEKLAFFKQHLKG
 270 280 290 300 HIS 310

↑ Asp

GC 392

Figure 6

10/15

10 30
ttgattttagagaaaagaagatttccgtcgccaagccagcatgtgcgt
L I V E K R R F P S P S Q H V R

50 70 90
ttgtatacgtatctgctatctgtcaaattggattacgggttaaggggctt
L Y T I C Y L S N G L R V K G L

110 130
ctggctgagccggcggaaccgggacaatatgacggatttttatatttg
L A E P A E P G Q Y D G F L Y L

150 170 190
cgccggcgggattaaaaggcgatggatggccggccggccggattatc
R G G I K S V G M V R P G R I I

210 230
cagtttgcattccaaagggttttgtggatgttcacagaggc
Q F A S Q G F V V F A P F Y R G

250 270 2
aatcaaggaggagaaggcaatgaggatttgcggagaagacagggag
N Q G G E G N E D F A G E D R E

90 310 330
gatgcattttctgccttcgcctgcattcagcagcacccaaatgtcaag
D A F S A F R L L Q Q H P N V K

350 370
aaggatagaatccatatttcggtttcccgccggcgaattatggga
K D R I H I F G F S R G G I M G

390 410 430
atgcactactgcgatcgaaatggcgccggcaggcagcattgtttcc
M L T A I E M G G Q A A S F V S

450 470
tgccggaggcgctcagtgatatgattttcacatcgaggagcggcaggat
W G G V S D M I L T Y E E R Q D

490 510 5
ttgcggcgaatgtgaaaagagtcatcgccggaaacaccgaaaaaggtg
I R R M M K R V I G G T P K K V

530 550 570
cctgaggaatatcaatggaggacaccgtttgaccaagtaaacaaaatt
P E E Y Q W R T P F D Q V N K I

590 610
caggctcccgctgttaatccatggagaaaaagacccaaatgtttcg
Q A P V L L I H G E K D Q N V S

630 650 670
atcagcattccatttatttagaagagaagctaaaacaactgcataag
I Q H S Y L L E E K L K Q L H K

690 710

GC 382 Figure 7A

105

ccgggtggaaacatggtactacagtacattcacacattttcccccca
P V E T W Y Y S T F T H Y F P P

730 750 7
aaagaaaaccggcgatcgtgcggcagctcacacaatggataaaaac
K E N R R I V R Q L T Q W M K N

70
cgc
R

GC 382 Figure 7B

115

gaacgcctgcaatttatcgagatgaaaacgctgaccataaagtcccg
E R L Q F I G D E N A D H K V P

730 750
cgggcagctgtttaaaaacgattgaatgtttgaaacgtactta
R A A V L K T I E W F E T Y L

GC 382 Figure 8B

14113

10 30
 ttgaagaaaatcctttggccattggcgccgtcgtaacagctgtcatc
 L K V K I L L A I G A L V T A V I
 . .
 50 70 90
 gcaatcggattgttttcacatatgatttattcatcaagaaaaaa
 A I G I V F S H M I L F I K K K
 110 130
 acggatgaagacattatcaaagagagacagacaacggacatgtgt
 T D E D I I K R E T D N G H D V
 150 170 190
 tttgaatcatttgaacaaatggagaaaaccgtttgtgataaccctcc
 F E S F E Q M E K T A F V I P S
 210 230
 gcttacgggtacgacataaaaggataccatgtcgccaccgcacaca
 A Y G Y D I K G Y H V A P H D T
 250 270 2
 ccaaataccatcatcatctgccacgggtgacgatgaatgtactgaat
 P N T I I C H G V T M N V L N
 90 310 330
 tctcttaagtatgcattattcttagatctcggtggaatgtgctc
 S L K Y M H L F L D L G W N V L
 350 370
 atttatgaccatcgccggcatggccaaagcggcggaaagacgaccagc
 I Y D H R R H G Q S G G K T T S
 390 410 430
 tacgggttttacaaaaaggatgatctcaataagggtgtcagcttgctc
 Y G F Y E K D D L N K V V S L L
 450 470
 aaaaacaaaaacaaatcatcgccgattgatcgaaattcatggtagtcg
 K N K T N H R G L I G I H G E S
 490 510 5
 atggggccgtgaccgcctgtttatgctggtgacactgcagcgt
 M G A V T A L L Y A G A H C S D
 30 550 570
 ggcgctgattttatattgccattgtccgtcgcatgtttgatgaa
 G A D F Y I A D C P F A C F D E
 590 610
 cagcttgcctatcggtgagagcggaaatacaggctccgtcttggccc
 Q L A Y R L R A E Y R L P S W P
 630 650 670
 ctgcttccatcgccgacttcttttgaagctgagggggaggctatcgc
 L L P I A D F F L K L R G G Y R

690

GC 382 Figure 9A

17/1
gcacgtgaagtatctccgcttgcgtcattgataaaattgaaaagccg
A R E V S P L A V I D K I E K P

730 750 7
gtcctcttttattcacagtaaggatgatgactacattcctgtttttca
V L F I H S K D D D Y I P V S S

70 790 810
accgagcggctttatgaaaaagaaaacgcggccgaaagcgctgtacatt
T E R L Y E K K R G P K A L Y I

830 850
gccgagaacggtaaacacgcacatgtcatataaccaaaaatcgccatacg
A E N G E H A M S Y T K N R H T

870 890 910
taccgaaaaacagtgcaggagtttttagacaacatgaatgattcaaca
Y R K T V Q E F L D N M N D S T

gaa
E

GC 382 Figure 9B